In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 6, 1997, Pages 885-888

  Hoffner, Sven E ^a,b   Gezelius, Lena ^a   Olsson Liljequist, Barbro ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SPARFLOXACIN; TROVAFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; FLUORINATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 0031436704     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.6.885     Document Type: Article

References (10)

1. Gorzynski, E. A., Gutman, S. I. & Allen, W. (1989). Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrobial Agents and Chemotherapy 33, 591-2.
2. Rastogi, N. & Goh, K. S. (1991). In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrobial Agents and Chemotherapy 35, 1933-6.
3. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 40, 1610-6.
4. Cavalieri, S. J., Biehle, J. R. & Sanders, W. E. (1995). Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 39, 1542-5.
5. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing; Sixth Informational Supplement. Document M100-S6. NCCLS, Wayne, PA.
6. Snider, D. E., Good, R. C., Kilburn, J. O., Laskowski, L. F., Lusk, R. H., Marr, J. J. et al. (1981). Rapid drug susceptibility testing of Mycobacterium tuberculosis. American Review of Respiratory Diseases 123, 402-6.
7. Hoffner, S. E., Svenson, S. B. & Källenius, G. (1987). Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. European Journal of Clinical Microbiology 6, 530-5.
8. Child, J., Andrews, J., Boswell, F., Brenwald, N. & Wise, R. (1995). The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy 35, 869-76.
9. Jacobs, M. R. (1995). Activity of quinolones against mycobacteria. Drugs 49, Suppl. 2, 67-75.
10. Mor, N., Vanderkolk, J. & Heifets, L. (1994). Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 14, 100-4.